Most Read Articles
Pearl Toh, 6 days ago
Adding the CDK4/6 inhibitor abemaciclib to an endocrine therapy of fulvestrant extends overall survival (OS) compared with fulvestrant alone in East Asian patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who have progressed on prior endocrine therapy, consistent with results from the overall population, updated analysis of the global, phase III MONARCH 2 study has shown.
01 Sep 2020
Acute diarrhoea is the second leading cause of deathin children aged younger than 5 years, accounting forapproximately 1.9 million deaths worldwide each year;however, diarrhoea is a preventable and treatable condition.In Malaysia, acute gastroenteritis accounts for about 1.3%of all deaths in children aged younger than 5 years annually.Diarrhoea is defined as the passage of three or more looseor watery stools within 24 hours, and it may be clinicallycategorised as either acute watery diarrhoea (AWD), acutebloody diarrhoea, persistent diarrhoea or diarrhoea withsevere malnutrition.

Common IBD biologics safe for pregnant women

31 Dec 2020

In pregnant women with inflammatory bowel disease (IBD), the use of vedolizumab or ustekinumab poses no negative effect on maternal or neonatal outcomes, according to a study.

The analysis used data from the PREGNANCY‐GETAID study and involved women with IBD who received either biologic drug during pregnancy or within 2 months before conception and compared outcomes to women treated with an anti‐tumour necrosis factor (TNF) during pregnancy (control).

A total of 73 pregnancies in 68 women were included, of which 29 were exposed to ustekinumab and 44 to vedolizumab. The control group comprised 88 pregnancies exposed to anti‐TNF in 76 women.

In the ustekinumab group, there were 26 live births (90 percent), two spontaneous abortions (7 percent), and one elective termination (3 percent). In the vedolizumab group, there were 38 live births (86 percent), five spontaneous abortions (11 percent), and one medical interruption (3 percent).

The median age at conception, the proportion of women who smoked, or clinical activity status at conception was comparable across the three groups. However, significantly more patients in the ustekinumab and vedolizumab groups than in the control group were exposed to more than two anti‐TNF agents (22 percent and 10 percent vs 3 percent; p<0.005).

Rates of prematurity, spontaneous abortion, congenital malformations, and maternal complications were similar in the three groups.

Additional prospective studies are needed to establish outcomes of pregnancies with new biologic drugs.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Adding the CDK4/6 inhibitor abemaciclib to an endocrine therapy of fulvestrant extends overall survival (OS) compared with fulvestrant alone in East Asian patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who have progressed on prior endocrine therapy, consistent with results from the overall population, updated analysis of the global, phase III MONARCH 2 study has shown.
01 Sep 2020
Acute diarrhoea is the second leading cause of deathin children aged younger than 5 years, accounting forapproximately 1.9 million deaths worldwide each year;however, diarrhoea is a preventable and treatable condition.In Malaysia, acute gastroenteritis accounts for about 1.3%of all deaths in children aged younger than 5 years annually.Diarrhoea is defined as the passage of three or more looseor watery stools within 24 hours, and it may be clinicallycategorised as either acute watery diarrhoea (AWD), acutebloody diarrhoea, persistent diarrhoea or diarrhoea withsevere malnutrition.